novo nordisk glp-1 receptor agonists weight management diabetes treatments McKee's proposed FY2027 budget drops drugs for loss from Medicaid Saxenda (liraglutide) for the Treatment

Eli Lilly, on the other hand, is increasing its manufacturing capacity with a $9 billion investment in Indiana and new facilities in Germany and Wisconsin

and global prevalence of type 2 diabetes and obesity, advancements in drug development, and expanding indications for weight loss and cardiovascular health

Explore these data and more at iHeardSTL

In rare cases, more serious complications like intestinal obstruction have been reported in FDA labeling for some of these medications

Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND (abstract 924-P) Diabetes

For RFS, the survival probabilities at five and 10 years were 95% and 90.9% with GLP-1RAs and 93.8% and 89.9% with SGLT2 inhibitors, respectively